Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003
Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003
复制标题
DOI：
10.1016/j.canrad.2016.02.009
复制
发表时间：
2016-06-01
影响因子：
1.3
通讯作者：
Chauveinc, L.
中科院分区：
文献类型：
--
作者：
Cosset, J. -M.;Flam, T.;Chauveinc, L.
目的. - 分析1999年至2003年治疗的675例患者的长期总生存率、无复发生存率和晚期毒性，中位随访时间为132个月。- 该队列包括低风险患者和选择的“有利-中等”风险患者。所有患者均采用术中动态计划前列腺近距离放射治疗技术进行治疗，使用松散的125碘粒子。393例患者（58%）接受了激素治疗，其中最常见的是单用抗雄激素。- 10年总生存率为92%（95%置信区间[CI]：90-94），低危组和选定的中危组之间无显著差异（P=0.17）。整个队列的10年无复发生存率为82%（95%CI：79-85），低危组显著高于中危组（87 vs 71%; P
Purpose. - To analyse long-term overall survival, relapse-free survival and late toxicities in a series of 675 patients treated between 1999 and 2003, with a median follow-up of 132 months.Patients and methods. - The cohort included low-risk patients and a selection of "favourable-intermediate" risk patients. All patients were homogeneously treated using an intraoperative dynamic planning prostate brachytherapy technique, with loose 125 iodine seeds. Hormone therapy, consisting most often of an anti-androgen alone, was given in 393 patients (58%).Results. - The 10-year overall survival was 92% (95% confidence interval [CI]: 90-94) without a significant difference between the low and the select intermediate-risk groups (P=0.17). The 10-year relapse-free survival rate for the entire cohort was 82% (95% CI: 79-85), and was significantly higher in the low-risk group than in the intermediate one (87 vs 71%; P